The most complex engineering of human cell lines ever has been achieved by scientists, revealing that our genomes are more resilient to significant structural changes than was previously thought.
Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the ...
Charity organisation Sickle Cell Society has described the recommendation as a “major breakthrough” for sickle cell patients.
Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...
Vertex Pharmaceuticals (VRTX) stock gains as England opts to reimburse its CRSPR (CRSP)-partnered gene therapy Casgevy to ...
NHS officials estimate around 50 people a year will receive treatment now it has been approved for use for certain patients with severe sickle cell disease. | ITV National News ...
The gene therapy Casgevy, which will now be offered to some patients in England, could help people live disease-free, experts ...
People in England to benefit from groundbreaking one-off gene therapy for severe sickle cell disease approved by NICE ...
Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® ...
NHS officials estimate that around 50 people a year will receive treatment now that it has been approved for use for certain ...
Australian researchers have successfully introduced an improved version of Cas12a gene-editing enzyme in mice.